Anthera Pharmaceuticals , Nasdaq: ANTH
Developing anti-inflammatory therapies for acute coronary syndrome and lupus.
Industry: Health Care
First Day Return: +0.1%
| IPO Data | |
|---|---|
| IPO Date | 02/28/2010 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $42 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Hayward, CA, United States |
| Founded | 2004 |
| Employees at IPO | n/a |
| Website www.anthera.com | |
Anthera Pharmaceuticals (ANTH) Performance
